Dimensional Fund Advisors LP Trims Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Dimensional Fund Advisors LP trimmed its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 37.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 603,133 shares of the company’s stock after selling 363,320 shares during the quarter. Dimensional Fund Advisors LP owned 1.23% of Nurix Therapeutics worth $12,587,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. GAMMA Investing LLC boosted its position in Nurix Therapeutics by 299.8% in the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after buying an additional 3,424 shares during the period. EntryPoint Capital LLC bought a new stake in shares of Nurix Therapeutics during the first quarter valued at approximately $123,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Nurix Therapeutics by 67.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock valued at $138,000 after acquiring an additional 3,793 shares in the last quarter. ProShare Advisors LLC boosted its holdings in shares of Nurix Therapeutics by 9.1% in the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after purchasing an additional 998 shares during the period. Finally, Caxton Associates LP bought a new position in Nurix Therapeutics in the first quarter worth approximately $225,000.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on NRIX shares. Royal Bank of Canada increased their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Friday, July 12th. Oppenheimer increased their target price on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, September 4th. HC Wainwright lifted their price objective on shares of Nurix Therapeutics from $19.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, June 18th. Robert W. Baird started coverage on Nurix Therapeutics in a report on Friday, September 6th. They set an “outperform” rating and a $26.00 target price for the company. Finally, Barclays lifted their price target on Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, July 15th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $27.00.

Nurix Therapeutics Trading Up 2.4 %

Shares of Nurix Therapeutics stock opened at $22.20 on Friday. The firm’s 50 day simple moving average is $23.18 and its two-hundred day simple moving average is $18.93. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -7.60 and a beta of 2.22. Nurix Therapeutics, Inc. has a 12-month low of $4.22 and a 12-month high of $26.31.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Thursday, July 11th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.08). Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. The business had revenue of $12.09 million during the quarter, compared to analyst estimates of $19.35 million. On average, sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.95 EPS for the current fiscal year.

Insider Activity

In related news, CFO Houte Hans Van sold 2,490 shares of the business’s stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total value of $51,468.30. Following the completion of the transaction, the chief financial officer now directly owns 54,479 shares in the company, valued at $1,126,080.93. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Christine Ring sold 5,760 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $21.43, for a total value of $123,436.80. Following the transaction, the insider now owns 24,592 shares in the company, valued at $527,006.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Houte Hans Van sold 2,490 shares of Nurix Therapeutics stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $51,468.30. Following the completion of the sale, the chief financial officer now directly owns 54,479 shares in the company, valued at $1,126,080.93. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 59,815 shares of company stock valued at $1,424,931 in the last quarter. 7.20% of the stock is currently owned by company insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.